DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Other: Blood Sample Collection - Observational Study
Other: Symptom questionnaires - Observational Study

First Posted Date: 2021-06-01

Last Posted Date: 2023-04-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT04908852

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Acalabrutinib in CNSL

Phase 1

Recruiting

Conditions: Refractory Central Nervous System Lymphoma
Central Nervous System Lymphoma
Recurrent Central Nervous System Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2021-05-28

Last Posted Date: 2024-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT04906902

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2

Terminated

Conditions: Melanoma
Metastatic Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Troriluzole
Drug: Placebo

First Posted Date: 2021-05-25

Last Posted Date: 2024-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT04899921

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

Phase 2

Recruiting

Conditions: Brain Cancer
Brain Metastases
Lung Cancer
Colorectal Cancer
Gastrointestinal Cancer
SRS
Melanoma
Breast Cancer
HER2-positive Breast Cancer
SRT

Interventions: Radiation: Stereotactic Radiation
Drug: AGuIX gadolinium-based nanoparticles
Other: Placebo

First Posted Date: 2021-05-25

Last Posted Date: 2024-10-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 134

Registration Number: NCT04899908

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

ATEMPT 2.0: Adjuvant T-DM1 Vs TH

Phase 2

Recruiting

Conditions: HER2-positive Breast Cancer
Breast Cancer

Interventions: Drug: trastuzumab-emtansine
Drug: Trastuzumab SC
Drug: Paclitaxel

First Posted Date: 2021-05-19

Last Posted Date: 2024-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 500

Registration Number: NCT04893109

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Smilow Cancer Hospital Care center at Derby, Derby, Connecticut, United States
🇺🇸
Smilow Cancer Hospital Care center at Fairfield, Fairfield, Connecticut, United States

and more 46 locations

Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial

Not Applicable

Recruiting

Conditions: Adenoid Cystic Carcinoma
Metastatic Adenoid Cystic Carcinoma

Interventions: Other: Standard of Care
Radiation: SBRT

First Posted Date: 2021-05-12

Last Posted Date: 2024-10-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT04883671

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Routine Evaluation of the Social Determinants of Health in Oncology: User-centered Resource Coordination and Engagement

Not Applicable

Completed

Conditions: Gastrointestinal Cancer
Breast Cancer
Lung Cancer

Interventions: Other: Resource Matching
Other: Usual Care

First Posted Date: 2021-05-10

Last Posted Date: 2023-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 125

Registration Number: NCT04879927

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Survivor-Sleep Health Information Program

Not Applicable

Completed

Conditions: Pediatric Cancer
Sleep Problem
Insomnia

Interventions: Behavioral: Survivor-SHIP

First Posted Date: 2021-04-28

Last Posted Date: 2023-01-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04863157

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Monoclonal Gammopathy of Undetermined Significance
Smoldering Multiple Myeloma

Interventions: Drug: Metformin XR
Other: Placebo

First Posted Date: 2021-04-20

Last Posted Date: 2024-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT04850846

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana-Farber at Merrimack Valley, Methuen, Massachusetts, United States
🇺🇸
DF/ BWCC in Clinical Affiliation with South Shore Hospital, Weymouth, Massachusetts, United States

and more 4 locations

Dilute Bleach Compresses for Radiation Dermatitis

Early Phase 1

Withdrawn

Conditions: Radiation Dermatitis

Interventions: Drug: Di-Dak-Sol
Other: White Petrolatum

First Posted Date: 2021-04-20

Last Posted Date: 2022-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT04851522

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy